Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.

被引：5
|
作者：
Mehmi, Inderjit [1 ,2 ]
Hill, Jordan [1 ,2 ]
机构：
[1] WVU Med, WVU Canc Inst, Morgantown, WV USA
[2] WVU Canc Inst WVU Med, Morgantown, WV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e21552
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21552
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma
    Aya, Francisco
    Gaba, Lydia
    Victoria, Ivan
    Fernandez-Martinez, Aranzazu
    Tosca, Monica
    Prat, Aleix
    Arance, Ana
    [J]. FUTURE ONCOLOGY, 2016, 12 (23) : 2683 - 2688
  • [2] Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma
    Zimmer, Lisa
    Apuri, Susmitha
    Eroglu, Zeynep
    Kottschade, Lisa A.
    Forschner, Andrea
    Gutzmer, Ralf
    Schlaak, Max
    Heinzerling, Lucie
    Krackhardt, Angela M.
    Loquai, Carmen
    Markovic, Svetomir N.
    Joseph, Richard W.
    Markey, Kelly
    Utikal, Jochen S.
    Weishaupt, Carsten
    Goldinger, Simone M.
    Sondak, Vernon K.
    Zager, Jonathan S.
    Schadendorf, Dirk
    Khushalani, Nikhil I.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 75 : 47 - 55
  • [3] Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma
    Patrinely, James R., Jr.
    Baker, Laura X.
    Davis, Elizabeth J.
    Song, Haocan
    Ye, Fei
    Johnson, Douglas B.
    [J]. CANCER, 2020, 126 (15) : 3448 - 3455
  • [4] Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
    Babacan, Nalan Akgul
    Eroglu, Zeynep
    [J]. CURRENT ONCOLOGY REPORTS, 2020, 22 (04)
  • [5] Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy
    Nalan Akgul Babacan
    Zeynep Eroglu
    [J]. Current Oncology Reports, 2020, 22
  • [6] Outcomes after progression of disease with anti-PD-1/PDL1 therapy for advanced melanoma
    Patrinely, James R.
    Wang, Laura X.
    Davis, Elizabeth J.
    Johnson, Douglas B.
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [7] Anti-PD-1 Therapy in Melanoma
    Moreno, Blanca Hornet
    Parisi, Giulia
    Robert, Lidia
    Ribas, Anton
    [J]. SEMINARS IN ONCOLOGY, 2015, 42 (03) : 466 - 473
  • [8] Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
    Olson, Daniel J.
    Eroglu, Zeynep
    Brockstein, Bruce
    Poklepovic, Andrew S.
    Bajaj, Madhuri
    Babu, Sunil
    Hallmeyer, Sigrun
    Velasco, Mario
    Lutzky, Jose
    Higgs, Emily
    Bao, Riyue
    Carll, Timothy C.
    Labadie, Brian
    Krausz, Thomas
    Zha, Yuanyuan
    Karrison, Theodore
    Sondak, Vernon K.
    Gajewski, Thomas F.
    Khushalani, Nikhil, I
    Luke, Jason J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (24) : 2647 - +
  • [9] Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma
    Li, Mengqian
    [J]. LANCET ONCOLOGY, 2021, 22 (08): : E342 - E342
  • [10] Anti-PD-1 therapies—a new first-line option in advanced melanoma
    Ryan J. Sullivan
    Keith T. Flaherty
    [J]. Nature Reviews Clinical Oncology, 2015, 12 : 625 - 626
12345